Sunday, November 23, 2014

Roth starts med tech focus list

October 25, 2011 by · Leave a Comment 

Roth Capital Partners has established a medical technology focus list, highlighting stocks that it believes offer attractive near-term trading opportunities.

Roth launched the focus list with “buy” rated AtriCure (NASDAQ:ATRC). Last week, Roth raised its target price on AtriCure to to $15 from $13.50, heading into the company’s FDA advisory panel meeting tomorrow. The stock closed at $10.16 on Monday.

“This list will be actively managed, such that ideas will be removed if our near-term thesis changes or the stock performs well, thereby altering the risk-reward profile of the strategy,” writes analyst Matt Dolan. “At times, the list will have several names and might be empty at others.”

Print Friendly

Comments are closed.

Email Newsletters with Constant Contact
Google+